Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Age 18 to 70 years.~* Histologically-proven diffuse large B-cell lymphoma (DLBCL) by the World Health Organization (WHO) classification.~* Relapse after achieving initial remission or failure to achieve initial remission. Patients with residual radiographic abnormalities after primary therapy are eligible if abnormalities are postive by fluorodeoxyglucose (FDG)-positron emission tomography (PET) (FDG-PET).~* Receipt of 2 cycles of second-line therapy and FDG-PET positive per Stanford (central) review. FDG-PET to be done 2 weeks after cycle 2 of second line chemotherapy.~* Eastern Cooperative Oncology Group (ECOG) performance status \< 2~* Matched related or unrelated donor identified and available~* Bone marrow biopsy and cytogenetic analysis within 8 weeks of registration~* Pretreatment serum bilirubin \< 2 x the institutional upper limit of normal (ULN)~* Serum creatinine \< 2 x the institutional ULN and measured or estimated creatinine clearance \> 60 mL/min by the following formula (all tests must be performed within 28 days prior to registration):~  * Estimated Creatinine Clearance = (140 age) x weight (kg) x 0.85 if female 72 x serum creatinine (mg/dL).~* EKG within 42 days prior to registration with no significant abnormalities suggestive of active cardiac disease~* Patients must have a radionuclide ejection fraction within 42 days of registration. If the ejection fraction is \< 40%, the patient will not be eligible. If the ejection fraction is 40-50%, the patient will have a cardiology consult.~* Corrected diffusion capacity \> 55%.~* Sexually active males are advised to use an accepted and effective method of birth control~* Women of child-bearing potential are advised to use an accepted and effective method of birth control~* Patients must sign and give written informed consent in accordance with institutional and federal guidelines. Patients must be informed of the investigational nature of this study.~EXCLUSION CRITERIA~* Known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide~* Greater than Grade 2 sensory or motor peripheral neuropathy from prior vinca alkaloid use~* Requiring therapy for coronary artery disease, cardiomyopathy, dysrhythmia, or congestive heart failure~* Known to be human immunodeficiency virus (HIV)-positive. The antibody test for HIV must be performed within 42 days of registration.~* Prior chemotherapy other than corticosteroids administered within 2 weeks of the initiation of protocol therapy.~* Prior malignancy, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the patients has been disease-free for five years.~* Prior diagnosis of non-Hodgkin's lymphoma~* Active infection requiring oral or intravenous antibiotics~* Prior autologous or allogeneic hematopoietic cell transplantation~* Prior radioimmunotherapy~* Pregnant~* Lactating~DONOR ELIGIBILITY~* Related or unrelated HLA-identical donors who are in good health and have no contra-indication to donation~* No contra-indication for the donor to collection by apheresis of mononuclear cells mobilized by G-CSF at a dose of 16 µg/kg of body weight.~* Donors will be evaluated with a full history and physical examination.~* Virology testing including HIV; cytomegalovirus (CMV); Epstein-Barr virus (EBV); human T-lymphotropic virus (HTLV); rapid plasma reagin (RPR); Hepatitis A, B and C be performed within 30 days of donation.~* Prospective donors will be screened for CMV seroreactivity and seronegative donors will be utilized if available.~* If more than one human leukocyte antigen (HLA)-matched related donor exists, then the donor will be selected on the basis of CD31 allotype.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Auto-HCT followed by Allo-HCT for Poor-risk DLBCL (Type: EXPERIMENTAL): Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning \[total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)\] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; \& methylprednisolone.

Based on this trial design, predict the completion outcome and termination type (if applicable).